© Getty Images/sinology
Biotechnology
Biotechnology is crucial for health, nutrition and sustainable economic activity. With cutting-edge research we are promoting the development of new therapies and vaccines, strengthening industry and agriculture and ensuring that innovations reach people faster.
Our roadmap for biotechnology
Our roadmap for biotechnology sets out key milestones and goals. These make progress measurable and provide guidance for planning and implementation.
Sub-goal 1: Gene and cell therapies
We are developing Germany into a world-leading location for the development, manufacture and commercial application of gene and cell therapies – from basic research to scalable GMP manufacturing – thereby securing a complete, sovereign value chain in Germany and Europe.
Translation centre for gene and cell therapies completed, in which start-ups can quickly turn their ideas into products
Description
Open the translation centre for gene and cell therapies.
Gene- and cell-based therapies are currently among the most important developments in precision medicine and aim to treat, prevent or possibly cure diseases at the cellular or genetic level. The translation centre offers the unique feature that an incubator area and a GMP facility (certified production site) are available under one roof for up to 20 start-ups. This is intended to translate ideas into concrete treatment options significantly faster.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- Opening of the building (target: 2nd half of 2028)
Measures
Support the establishment of a translation centre for gene and cell therapy
Partners
- BIH
- Companies
- Charité
Transfer from research into healthcare provision significantly accelerated by strengthening start-ups and improving links with industry
Description
Create space for new start-ups and significantly increase the number of collaborations with industry
in order to accelerate the transfer from research into healthcare provision.
The growth potential of gene- and cell-based therapies in the coming years is of great importance for research, industry and patient care. Accelerating technology transfer is therefore particularly significant here.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Number of new start-ups in the field of gene and cell therapy (target: 20 in the gene and cell therapy translation centre alone)
Number of collaborations/collaborative projects (target: 30 in the gene and cell therapy translation centre alone)
Measures
Support the establishment of a translation centre for gene and cell therapy
ATMP (Advanced Therapies Medicinal Products) Centres of Excellence
Partners
- BIH
- Companies
- Charité
- Universities
- Research Institutions
- Industry
- SPRIND
Process from idea to clinical trial in the field of gene and cell therapy significantly accelerated
Description
Translation of promising approaches in gene- and cell-based therapies into patient care significantly accelerated in order to secure and expand shares of value creation in international comparison.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Time from idea to conduct of a clinical trial (target: 30% faster)
Number of automation and platform technologies used (cf. BT-WS4)
Regulatory hurdles for authorisation of clinical trials (target: significantly reduced)
Measures
Support the establishment of a translation centre for gene and cell therapy
Partners
- BC-GCT
- Industry
Number of clinical trials in gene and cell therapies increased by 30%
Description
Develop safe, efficient and sustainably financeable therapies and significantly strengthen the international competitiveness of Germany as a location in this field.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Number of clinical trials in gene and cell therapies (target: 120)
Germany's position in European comparison in terms of the number of clinical trials (target: leading)
Measures
Support the establishment of a translation centre for gene and cell therapy
Partners
- BC-GCT
- Industry
Skills base for gene and cell therapies broadened, in particular through additional trained GMP specialists
Description
Ensure a broad and well-qualified skills base for gene and cell therapies in Germany. The training and support module of the translation centre will significantly expand expertise in the field of GCT and biotechnology in Berlin and throughout Germany.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Commissioning of the GMP facility
Capacity utilisation of the GMP facility
Number of GMP specialists trained
Partners
- BIH
- Companies
Technology-driven translational infrastructure for infection medicine in operation
Description
Next Generation infection medicine – photonic system development, AI-based data analysis, clinical validation, regulatory preparation and industrial value creation prospects of end-to-end translation processes.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- Target 2028: first-in-patient unit for patient-centred technology testing in operation (target: 2028)
Partners
- Universities
- LPI gGmbh
- Research Institutions
- Companies
Sub-goal 2: Network University Medicine
We are establishing a joint national competence network of university hospitals so that excellent quality of care is available throughout Germany and not only at individual centres of excellence.
R&D infrastructures built up and made available for all German university hospitals
Description
Build up joint infrastructures for clinical trials that are accessible to all, so that Germany can once again be among the world leaders as a location for clinical trials.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- Continuation of NUM decided
Partners
- NUM
- University Hospitals
Germany positioned among the top three in the global ranking of locations for clinical trials
Description
A central point of contact and coordinator in the sense of a “one-stop shop” for the whole of German university medicine will be available, for example for the pharmaceutical industry.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Number of clinical trials (with industrial partners)
Number of active substances tested
Partners
- NUM
- University Hospitals
Broad access to quality-assured human biosamples and other relevant data established
Description
Provide access to quality-assured human biosamples and other relevant data (both associated with the biosamples and beyond) for the whole of clinical research in Germany in order to answer relevant R&D questions. To this end, data from (university) clinical care and research are brought together in NUM, made available to medical research and connected at European level by March 2029.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Opening of the National Biobank
Number of projects carried out using the participating biobanks per calendar year (target: increase to 1,800 p.a. by 2029)
Connection of NUM to the EHDS
Number of data access/data linkage applications (NUM, DACO/EHDS)
Provision of data via a secure processing environment (SPE)
Partners
- NUM
- University Hospitals
- DACO
Access to innovative therapies significantly improved through broader involvement of patients in clinical trials
Description
Improve patients' access to clinical trials, as clinical trials are the decisive step in enabling medical progress and improving therapies. They offer patients early access to innovative treatment options.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Number of patients in clinical trials (target: in NUM alone: approx. 100 trials per year involving approx. 10,000 patients p.a.)
Qualification of patients as multipliers for recruitment into clinical trials
Partners
- NUM
- University Hospitals
Sub-goal 3: Next Generation BioTech
We are unlocking the economic and scientific potential of biotechnology for Germany by specifically expanding research capacities, actively supporting start-ups and established companies in building up new bio-based value chains and thereby contributing to a significant acceleration of medical innovations.
First mRNA cancer immunotherapy authorised
Description
mRNA cancer immunotherapies are treatments in which mRNA is introduced into the body in order to train the immune system to recognise tumour-specific features and attack cancer cells. Such therapies can be tailored individually to a patient's tumour.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- First authorisation of an mRNA cancer immunotherapy or an mRNA cancer vaccine (therapeutic vaccine)
Partners
- Industry
More diagnostic point-of-care (POC) tests available for patients in hospital or at home
Description
Increase the number of available POC tests so that analyses can be carried out at home or directly at the place of treatment and treatment options can be discussed with patients immediately.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- Number of POC tests available for patients
Partners
- Universities
- Research Institutions
- Industry
Genome sequencing capacities expanded
Description
Expand genome sequencing capacities in Germany for research into innovative personalised diagnostics and therapy within the framework of the Genome Sequencing Model Project pursuant to Section 64e SGB V. This makes it possible to investigate possible causal changes in the genome and molecular mechanisms, to enable more targeted and faster development of medicines and to diagnose and predict disease risks, treatment options and treatment courses in a differentiated manner.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- Number of available data sets
- Number of data use applications
Partners
- BfArM
- RKI
- University Hospitals
- Companies
Platform technologies and biofoundries established and approved that halve the development time and costs of complex biotherapeutics
Description
Authorise platform technologies such as mRNA, gene vectors, antibodies and cell therapies with which the development time and costs of complex biotherapeutics can be halved.
Biotechnological platform technologies are standardised systems that serve as a basis and blueprint for the development of a wide range of different products (e.g. medicines, vaccines, gene and cell therapies). Instead of starting “from scratch” for every new product, a platform makes it possible to use proven processes and technologies, which increases efficiency, speed and quality and thus reduces the time and cost of developing new therapies.
Biofoundries are highly automated research and development platforms designed to engineer, build and test biological systems quickly, in a standardised way and on a large scale with the help of AI and robotics.
This milestone also contributes to sub-goals 1, 2 and 4.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Number and type of (approved) platform technologies and established biofoundries in broad use (industry, clinical practice)
Development time and costs of complex biotherapeutics (target: halved)
Partners
- Universities
- Research Institutions
- Industry
Significantly faster diagnoses are made possible, among other things, by AI-supported analyses.
Description
Introduce rapid diagnostics, i.e. significantly faster diagnoses are made possible, among other things, by automation, multi-omics technologies and AI-supported analyses.
Faster diagnostics allow treatment options to be discussed with patients promptly or even immediately, which can improve the chances of recovery and prevent complications.
This milestone also contributes to sub-goals 1 and 2.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Time from test to analysis for certain indications (e.g. tumour diagnostics following biopsy/histology)
Number of AI tools and AI agents introduced and, where applicable, approved for diagnostic purposes
Measures
Use the GO-Bio biotechnology funding programme to accelerate the transfer of innovative, promising ideas from the laboratory to the market
Partners
- Universities
- Research Institutions
- Industry
Innovative medicines or functional proteins for diagnostic procedures brought to people faster with the help of AI
Description
Use of novel AI methods for drug development is established.
New AI technologies are advanced artificial intelligence systems based on modern methods such as machine learning, deep learning and generative models that are able to analyse complex data independently, recognise patterns and develop predictions or solutions. They go beyond classical statistical analyses and are used for analysis, modelling, decision preparation and the generation of new active substances. The early development of medicines in particular (finding target structures, designing active substances) can be decisively accelerated.
Functional proteins can be specifically “designed” for new diagnostic procedures and therapies – with high commercialisation potential.
This milestone also contributes to sub-goals 1 and 2.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Number of medicines developed with the help of AI
Number of AI tools and AI agents introduced and, where applicable, approved for drug development and clinical trials
Significant shortening of a defined research and development phase
Availability of standardised data and reference data sets
Measures
Use the GO-Bio biotechnology funding programme to accelerate the transfer of innovative, promising ideas from the laboratory to the market
Partners
- Industry
- Universities
- Research Institutions
Sub-goal 4: Entrepreneurship
We are strengthening entrepreneurship in biotechnology in Germany and supporting transfer in order to turn excellent research into globally competitive companies.
Share of venture capital in the biotechnology sector significantly increased
Description
Use a combination of infrastructure support, financial incentives and a clear policy strategy to significantly increase venture capital (VC) in German biotechnology by 2030, thereby strengthening the sector's capacity for innovation over the long term.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- Amount of VC capital available (investment commitments)
Partners
- BIH
- Innovation-/Life-Science Clusters
- Capital Providers / Investors
- Länder
- SPRIND
Number of marketable spin-offs in biotechnology significantly increased
Description
Support spin-offs by strengthening infrastructure for start-ups.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
- Number of spin-offs (target: founding of at least five new life science companies)
Measures
Use the GO-Bio biotechnology funding programme to accelerate the transfer of innovative, promising ideas from the laboratory to the market
Partners
- BIH
- Universities
- Länder
- Research Institutions
- Innovation-/Life-Science Clusters
More SME innovations “Made in Germany” brought to product maturity and onto the market
Description
Produce more internationally competitive “Made in Germany” products.
Targeted SME support measures such as KMU-innovativ: Biomedizin or KMU-innovativ: Medizintechnik for medical technology strengthen industry's innovative capacity. This contributes to industrial production, jobs and strategic sovereignty.
This milestone also contributes to sub-goals 2 and 4.
Goals
Health research
Through biotechnology we will strengthen Germany's sovereignty in developing the medicine of tomorrow and thereby make Germany a leading location for health research.
Indicators
Number of licensing deals concluded
Number of research and development staff
Turnover of companies in biotechnology and medical technology
Partners
- SMEs
Goal 2: The most innovative location
We will develop Germany into the world's most innovative location for biotechnology, thereby shaping a resource-efficient, competitive industry and increasing Germany's value creation.
Innovation hub for AI-based bioprocess development launched
Description
Dramatically shorten the time from idea to market by accelerating bioprocess development.
Goals
The most innovative location
We will develop Germany into the world's most innovative location for biotechnology, thereby shaping a resource-efficient, competitive industry and increasing Germany's value creation.
Indicators
Average development time for bioprocesses (target: development time halved)
Measures
Industrial bioeconomy
Partners
- Universities
- Research Institutions
- Chemistry & Biotechnology Companies
- SMEs
- BioDigitalHubs
- BMFTR
Private investment in research, development and scaling increased to EUR 5 billion per year
Description
Increase private investment in research and development through close cooperation between industry and science and thereby enhance competitiveness and future value creation.
In particular, existing funding gaps are closed and commercial uptake is accelerated by integrating different programmes, including a simple funding format tailored to industry needs (e.g. within public-private partnerships) and funding formats for scaling up new bioprocesses.
The IPCEI supported by the Federal Government can also contribute here.
Within the framework of the Germany Fund, the supply of growth and innovation capital is to be expanded, which can also help to cover existing financing needs.
Goals
The most innovative location
We will develop Germany into the world's most innovative location for biotechnology, thereby shaping a resource-efficient, competitive industry and increasing Germany's value creation.
Indicators
Amount of private investment in R&D (target: €5 billion)
Ratio of private to public funds in the partnerships funded by the BMFTR (target: at least 1:1)
Measures
Industrial bioeconomy
Partners
- Central Chemistry & Biotechnology Companies in Germany
- SMEs
- Start-ups
- BMFTR
- BMWE
Accessibility for companies simplified at least to ten leading research and technology infrastructures
Description
Strengthen research and technology infrastructure, in particular improve the use of existing structures by 2028 and facilitate access, especially for companies (including through the establishment of a one-stop shop with uniform access conditions).
To this end, drive forward the establishment of a European Research Infrastructure Consortium (IBISBA-ERIC) by 2027 with the support of key implementation partners in industrial biotechnology.
Goals
The most innovative location
We will develop Germany into the world's most innovative location for biotechnology, thereby shaping a resource-efficient, competitive industry and increasing Germany's value creation.
Indicators
Number of R&D projects with companies increased (target: by 50%)
Capacity utilisation of research and technology infrastructures increased (target: by 50%)
Measures
Industrial bioeconomy
Partners
- Fraunhofer IGB/CBP
- TUM Bio Scale-up Center
- FZ Jülich
- TU Berlin
- RWTH Aachen
- University of Stuttgart
- UFZ
- SMEs
- Start-ups
- BMFTR
AI bioprocess platform established and development times for new bioprocesses halved
Description
Two BioDigitalHubs established in order to halve the development time for new bioprocesses
Goals
The most innovative location
We will develop Germany into the world's most innovative location for biotechnology, thereby shaping a resource-efficient, competitive industry and increasing Germany's value creation.
Indicators
Establishment of BioDigitalHubs by 2027 (target: two hubs)
Development of a digital bioprocess platform by 2029 (target: one platform)
Measures
Industrial bioeconomy
Partners
- Universities
- Research Institutions
- Chemistry & Biotechnology Companies
- SMEs
- Start-ups
- BioDigitalHubs
- BMFTR
Germany is the leading location for bioengineering in Europe
Description
Germany's specific technological strength (from strain/enzyme design to process development): here the advantages of a strong research landscape, mechanical and plant engineering and a manufacturing industry can be used to become the leading developer of sustainable and safe technologies in Europe, in particular at the interface between biotechnology and engineering (e.g. synthetic biology in a biofoundry).
Goals
The most innovative location
We will develop Germany into the world's most innovative location for biotechnology, thereby shaping a resource-efficient, competitive industry and increasing Germany's value creation.
Indicators
Start-ups founded by 2029 (target: 20)
Patent applications (target: among the top 3 in Europe)
Specialist publications (target: leading in Europe)
Measures
Industrial bioeconomy
Partners
- Research Institutions
- Biotechnology Companies
- Associations
- BMFTR
- BMWE
Share of revenue from bio-based chemicals increased to 15%
Description
Through R&D funding, support for the IPCEI Biotechnology, the removal of regulatory barriers and the commitment of industry, new bio-based products (chemicals, materials) are reaching the market and increasing bio-based value creation in Germany.
Goals
The most innovative location
We will develop Germany into the world's most innovative location for biotechnology, thereby shaping a resource-efficient, competitive industry and increasing Germany's value creation.
Indicators
Share of revenue from bio-based chemicals in total chemical sales (target: 15%)
Measures
Industrial bioeconomy
Partners
- Central Chemistry & Biotechnology Companies in Germany
- SMEs
- Start-ups
- BMFTR
- BMWE
- Associations
- Research Institutions
Goal 3: Agricultural and food systems
With biotechnology we will develop the resilient, crisis-proof agricultural and food systems of the future.
An industry-led innovation ecosystem for biotechnological foods established
Description
Establish Germany as the leading European location for precision fermentation and cell cultivation, including through the founding of an innovation hub for precision fermentation and cell cultivation in 2027, which will make the economic opportunities of these future technologies usable for the food industry.
Germany has strong research institutions and a promising start-up landscape in the field of biotechnological foods. By bundling publicly funded research activities and networking companies and research institutions, the existing innovation potential of a dynamically developing sector is to be realised.
Goals
Agricultural and food systems
With biotechnology we will develop the resilient, crisis-proof agricultural and food systems of the future.
Indicators
Number of start-ups
Number of company formations
Number of chairs for the relevant platform technologies
Number of skilled workers recruited
Amount of private investment (target: innovation hub founded)
Measures
Biotechnological foods
Partners
- Universities
- Research Institutions
- Business Partners
- BMFTR
- BMLEH
- BMWE
Initial and additional products for biotechnological foods from precision fermentation or cell cultivation developed in Germany (e.g. alternatives to traditional cheese, egg, meat or fish products) launched on the world market
Description
Precision fermentation and cell cultivation are future technologies of the food industry. With a strong biotech landscape and mechanical and plant engineering, Germany has the opportunity to become a leading technology developer for this global growth market. In order to achieve competitive production costs, specific technological milestones must be reached depending on the technologies concerned (e.g. cell densities >100 million cells/ml in stable cultures, halving of bioreactor costs, reduction of culture medium costs by 90%, etc.).
The requirement for novel foods to be authorised by the European Commission must also be taken into account.
Goals
Agricultural and food systems
With biotechnology we will develop the resilient, crisis-proof agricultural and food systems of the future.
Indicators
Number of products developed
Technical milestones for competitive production systems in the field of cell cultivation (targets: cell densities >100 million cells/ml in stable cultures; scale in 500–3,000 l reactors)
Measures
Biotechnological foods
Partners
- Universities
- Research Institutions
- Business Partners
- BMFTR
- BMLEH
- BMWE
Doubling the market share of innovative methods for protecting crops against damage from insects and pathogens and consolidating Germany's position as European leader in development and deployment
Description
Develop biotechnological crop protection systems by 2030 and, through their effectiveness, scalability and safety for humans, animals and the environment, contribute to sustainable agriculture.
Goals
Agricultural and food systems
With biotechnology we will develop the resilient, crisis-proof agricultural and food systems of the future.
Indicators
Market share of biotechnological crop protection (target: at least 10% by 2030)3
Germany the leader in Europe for sustainable crop protection (target: leading in scientific publications and patent applications)
Measures
Biotechnological plant breeding and crop protection
Partners
- Universities
- Research Institutions
- Business Partners
- BMFTR
- BMLEH
- BMUKN
- Authorities
Innovation cycles for new plants accelerated by one third,4 with Germany leading in Europe in the development of competitive varieties
Description
Modern biotechnological methods can accelerate breeding progress, as desired traits are introduced in a targeted way. The effectiveness of varieties developed and validated with the help of modern breeding methods is demonstrated.
Goals
Agricultural and food systems
With biotechnology we will develop the resilient, crisis-proof agricultural and food systems of the future.
Indicators
Germany the leader in Europe
(target: leading in scientific publications and patent applications)
Annual increase in productivity in cultivation (target: 1–2%)
Measures
Biotechnological plant breeding and crop protection
Partners
- Universities
- Research Institutions
- Business Partners
- BMFTR
- BMLEH
- Authorities